BG Medicine, Inc. Announces Schedule of Events Related to Galectin-3 at the 17th Annual Scientific Meeting of the Heart Failure

BG Medicine, Inc. Announces Schedule of Events Related to Galectin-3 at the
17th Annual Scientific Meeting of the Heart Failure Society of America

WALTHAM, Mass., Sept. 19, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a commercial stage company that is focused on the development
and delivery of diagnostic solutions to aid in the clinical management of
heart failure and related disorders announced today a series of events related
to galectin-3 and heart failure during the 17th Annual Scientific Meeting of
the Heart Failure Society of America (HFSA) taking place on September
22^nd-25^th, 2013 in Orlando, Florida.

OnSunday, September 22^nd, immediately following the opening session, BG
Medicinewill co-sponsor an Early Career Professionals Reception with Boston
Scientific Corporation. This event provides a rare opportunity for early
career professionals to meet mentors and talk with some of the most respected
heart failure specialists in America.

Galectin-3 will be featured in several oral presentations at the meeting
including one entitled, "Novel Biomarkers for Heart Failure – Eventual Targets
for Therapy" on Monday, September 23^rd at 4:00pm Eastern Time. Christopher
deFilippi, MD, Associate Professor of Medicine at the University of Maryland
will discuss Galectin-3 and the prognosis in heart failure during this
presentation.

OnTuesday, September 24^th,there will be a Galectin-3 presentation by Alan
Maisel, MD, Professor of Medicine and Director of the Coronary Care Unit at
the University of California San Diego and Michael Zile, MD, Principal
Investigator at the Gazes Cardiac Research Institute and Professor of Medicine
at Medical University in Charleston, South Carolina. The title of the program
is "Development, progression and hospitalization for heart failure: targeting
fibrosis" and will take place at 12:45pm Eastern Time in The Peabody Hotel
Exhibit Hall. This program will address the role of Galectin-3, a marker
implicated in cardiac fibrosis, in the development of heart failure (HF) and
how to use a biomarker guided approach to identify patients at high risk for
near term hospitalization and mortality.

About Galectin-3 Testing and Heart Failure

Galectin-3 has been implicated in a variety of biological processes important
in the development and progression of heart failure. Higher levels of
galectin-3 are associated with a more aggressive form of heart failure, which
may make identification of high-risk patients using galectin-3 testing an
important part of patient care. Galectin-3 testing may be useful in helping
physicians determine which patients are at higher risk of death or
hospitalization, including 30-day readmission. The BGM Galectin-3® blood test
is to be usedas an aid in assessing the prognosis of patients with chronic
heart failure, in conjunction with clinical evaluation. For more information
visit www.galectin-3.com

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a commercial stage company that is focused
on the development and delivery of diagnostic solutions to aid in the clinical
management of heart failure and related disorders. For additional information
about BG Medicine, heart failure and galectin-3 testing, please visit
www.BG-medicine.com. The BG Medicine Inc. logo is available for download here

CONTACT: BG-Medicine Investor Inquiries:
         Chuck Abdalian, EVP & Chief Financial Officer, (781) 434-0210

BG Medicine Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.